Andrew Fein
In May 2013, Andrew Fein joined H.C. Wainwright & Co. as managing director and senior biotechnology analyst to cover companies in the biotechnology and life sciences sectors. He has 13 years of experience in healthcare and biotechnology equity research. He was previously a senior analyst at Chardan Capital Markets and held prior research positions at Jefferies & Co., Piper Jaffrey, Collins Stewart, Leerink Swann LLC and J.P. Morgan.
Recent Articles
New Data Supports BLA Package 12/17/2024
Annexon Inc. (ANNX:NASDAQ) recently released real-world evidence data comparing it's ANX005 to standard treatments for Guillain-Barr Syndrome (GBS), according to an H.C. Wainwright & Co. research note.
H.C. Wainwright & Co. Raises Price Target on Biotech Following Positive Regulatory Updates 10/23/2024
DBV Technologies SA (DBVT:NASDAQ) received a raised target price after it released long-awaited regulatory clarity regarding the path forward for its Viaskin Peanut patch.
Pharma Co. Reports Positive Data for Leukemia Combination Therapy 12/06/2023
Recently, Syros Pharmaceuticals Inc. announced positive data for its Leukemia Combination Therapy, noted an H.C. Wainwright & Co. report.
Recent Quotes
"ATNM's two clinical programs offer a cheap long opportunity for investors interested in AML therapeutics."
—
Andrew Fein, H.C. Wainwright & Co.
(6/2/16)
more >
